Kjell Öberg is a scholar working on Epidemiology, Neurology and Oncology.
According to data from OpenAlex, Kjell Öberg has authored 402 papers receiving a total of 26.1k indexed citations (citations by other indexed papers that have themselves been cited), including 340 papers in Epidemiology, 231 papers in Neurology and 227 papers in Oncology. Recurrent topics in Kjell Öberg's work include Neuroendocrine Tumor Research Advances (340 papers), Neuroblastoma Research and Treatments (229 papers) and Lung Cancer Research Studies (174 papers). Kjell Öberg is often cited by papers focused on Neuroendocrine Tumor Research Advances (340 papers), Neuroblastoma Research and Treatments (229 papers) and Lung Cancer Research Studies (174 papers). Kjell Öberg collaborates with scholars based in Sweden, United States and Germany. Kjell Öberg's co-authors include Barbro Eriksson, Britt Skogseid, Eva Tiensuu Janson, Marianne Pavel, Anders Sundin, Erik Wilander, Mats Stridsberg, Aurel Perren, Göran Åkerström and Edward M. Wolin and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.
In The Last Decade
Kjell Öberg
389 papers
receiving
25.4k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
20112.1k citationsJames C. Yao, Manisha H. Shah et al.profile →
Gastroenteropancreatic neuroendocrine tumours
20081.2k citationsKjell Öberg, Wouter W. de Herder et al.profile →
Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma
1988794 citationsBritt Skogseid, Kjell Öberg et al.profile →
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011767 citationsMarianne Pavel, Robert Winkler et al.profile →
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
2016738 citationsMarianne Pavel, Jaume Capdevila et al.Neuroendocrinologyprofile →
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2020653 citationsMarianne Pavel, Kjell Öberg et al.profile →
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
2012616 citationsEric P. Krenning, Kjell Öberg et al.Neuroendocrinologyprofile →
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2012380 citationsKjell Öberg, Dik J. Kwekkeboom et al.profile →
ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum
2016315 citationsBruno Niederle, Kjell Öberg et al.Neuroendocrinologyprofile →
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
2018272 citationsJonathan Strosberg, Edward M. Wolin et al.Journal of Clinical Oncologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Kjell Öberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kjell Öberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kjell Öberg more than expected).
This network shows the impact of papers produced by Kjell Öberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kjell Öberg. The network helps show where Kjell Öberg may publish in the future.
Co-authorship network of co-authors of Kjell Öberg
This figure shows the co-authorship network connecting the top 25 collaborators of Kjell Öberg.
A scholar is included among the top collaborators of Kjell Öberg based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Kjell Öberg. Kjell Öberg is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Strosberg, Jonathan, Edward M. Wolin, Beth Chasen, et al.. (2016). NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results.. Neuroendocrinology. 103(5 Suppl 7). 629–629.19 indexed citations
5.
Kulke, Matthew H., Dieter Hoersch, Martyn Caplin, et al.. (2016). Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial. Pancreas. 45(3). 478–478.1 indexed citations
6.
Hoersch, Dieter, Michael Kulke, Emily K. Bergsland, et al.. (2016). Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome. Neuroendocrinology. 103. 89–89.1 indexed citations
7.
Wolin, Edward M., Barbara Jarząb, Barbro Eriksson, et al.. (2014). A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs. Pancreas. 43(3). 508–508.2 indexed citations
8.
Tao, Cui, Apostolos V. Tsolakis, Janet L. Cunningham, et al.. (2013). Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis of Small Intestine Neuroendocrine Tumors. Pancreas. 42(2). 373–373.4 indexed citations
9.
Shah, Manisha H., Kjell Öberg, Tetsuhide Ito, et al.. (2011). Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3). Pancreas. 40(2). 331–332.1 indexed citations
Kvols, Larry K., Bertram Wiedenmann, Kjell Öberg, et al.. (2010). Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR. Neuroendocrinology. 92(1). 42–43.5 indexed citations
12.
Wickström, Malin, et al.. (2010). The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.. PubMed. 30(1). 149–56.34 indexed citations
Örlefors, Håkan, Anders Sundín, Anders Lilja, et al.. (1998). Positron emission tomography (PET) with 5-hydroxytryptophan (5-HTP) in the diagnosis and treatment follow upp of carcinoid tumors. Journal of Clinical Oncology. 7. 2534.10 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.